Scientific Sessions 2025  /  Contemporary Controversies in Cardiac Transplantation and Circulatory Support Devices  /  A 30yo with giant cell myocarditis is on VA ECMO for cardiogenic shock and developed renal failure requiring CVVH. The next best step is to proceed with heart transplant and consider safety-net kidney transplant if renal function does not improve.
Logo

American Heart Association

  96
  0

Final ID:

A 30yo with giant cell myocarditis is on VA ECMO for cardiogenic shock and developed renal failure requiring CVVH. The next best step is to proceed with heart transplant and consider safety-net kidney transplant if renal function does not improve.

  • Mccallum, Wendy  ( Tufts Medical Center , Boston , Massachusetts , United States )
  • Cheng, Xingxing  ( Stanford University , Stanford , California , United States )
  • Rangaswami, Janani  ( George Washington University , Washington , District of Columbia , United States )
  • Khazanie, Prateeti  ( University of Colorado , Denver , Colorado , United States )
    • Author Disclosures:
    Wendy McCallum: DO NOT have relevant financial relationships | Xingxing Cheng: DO NOT have relevant financial relationships | Janani Rangaswami: No Answer | Prateeti Khazanie: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Contemporary Controversies in Cardiac Transplantation and Circulatory Support Devices

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
A 30yo with giant cell myocarditis is on VA ECMO for cardiogenic shock and developed renal failure requiring CVVH. The next best step is to wait 6 weeks for renal recovery and proceed to simultaneous heart-kidney transplant if renal function does not improve.

Arora Nayan, Bansal Nisha, Peters Laura, Allegretti Andrew

A 50yo Veteran with PTSD has inotrope-dependent HF from long-standing ischemic cardiomyopathy, currently smokes 1ppd (down from 2ppd), and is AB blood type. The next best treatment is durable LVAD.

Pirlamarla Preethi, Agarwal Richa

More abstracts from these authors:
Kidney Function is Dropping—Is It Time to Stop the ACE Inhibitor?

Mccallum Wendy, Inker Lesley

Worsening Renal Function in HFpEF: What’s the Best Game Plan?

Bansal Shweta, Mccallum Wendy

You have to be authorized to contact abstract author. Please, Login
Not Available